Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29019464 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2HIF1AKMT2AFABP5FABP7 | |
| SCHEMBL27522574 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2HIF1AKMT2AFABP5FABP7 | |
| SCHEMBL16634841 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2HIF1AKMT2AFABP5FABP7 | |
| SCHEMBL31522719 | 0.90 | HIF1A (0.44) | SMN1; SMN2HIF1AKMT2AFABP5FABP7 | |
| SCHEMBL28884667 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2HIF1AKMT2AFABP5FABP7 | |
| SCHEMBL28884665 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2HIF1AKMT2AFABP5FABP7 | |
| SCHEMBL1311053 | 0.89 | FABP5 (0.44) | SMN1; SMN2HIF1AKMT2AFABP5FABP7 | |
| SCHEMBL29019435 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2HIF1AKMT2AFABP5FABP7 | |
| SCHEMBL29019459 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2HIF1AKMT2AFABP5FABP7 | |
| SCHEMBL28356620 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2HIF1AKMT2AFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111432844-B | PSMA-targeting amanitine conjugates | 海德堡医药研究有限责任公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3684416-B1 | PSMA-TARGETING AMANITIN CONJUGATES | HEIDELBERG PHARMA RES GMBH (DE) | 2023-03-15 | — | — | EP | disclosed |
| US-11583569-B2 | PSMA-targeting amanitin conjugates | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-02-21 | — | — | US | disclosed |
| CN-110092814-B | Amphiphilic multi-block antibacterial peptide and preparation method and application thereof | 同济大学 | 2022-08-09 | — | — | CN | disclosed |
| EP-1756579-A2 | COLLECTIONS OF TRACEABLE COMPOUNDS AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-02-28 | — | — | EP | disclosed |
| CN-1262533-C | Synthetic method for Nalpha-9-fluorenylmethyloxycarbonyl-amino acid | SHANGHAI ZHONGYUAN CHEMICAL CO (CN) | 2006-07-05 | — | — | CN | disclosed |
| WO-2006003330-A2 | COLLECTIONS OF TRACEABLE COMPOUNDS AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-01-12 | — | — | WO | disclosed |
| CN-1504457-A | Synthetic method for Nalpha-9-fluorenylmethyloxycarbonyl-amino acid | 上海中远化工有限公司 | 2004-06-16 | — | — | CN | disclosed |
| US-6660832-B1 | Cyclic peptide compounds with fused benzene rings; solid phase synthesis thereof; use as antibiotic to treat bacterial infection in mammals; may work by binding to RNA targets | ISIS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| WO-2001014346-A1 | MACROCYCLIC COMPOUNDS AND PREPARATION METHODS THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583569-B2 | PSMA-targeting amanitin conjugates | FOLH1, ANPEP, PSMA6 | SMN1; SMN2 3323/4885HIF1A 1877/4885KMT2A 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.